A detailed history of Abn Amro Investment Solutions transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Abn Amro Investment Solutions holds 62,277 shares of HCM stock, worth $939,137. This represents 0.02% of its overall portfolio holdings.

Number of Shares
62,277
Previous 63,915 2.56%
Holding current value
$939,137
Previous $962 Million 1.97%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$14.83 - $19.21 $24,291 - $31,465
-1,638 Reduced 2.56%
62,277 $981 Million
Q2 2025

Aug 08, 2025

BUY
$11.81 - $17.72 $754,836 - $1.13 Million
63,915 New
63,915 $962 Million
Q4 2024

Sep 04, 2025

SELL
$14.25 - $21.35 $16,957 - $25,406
-1,190 Reduced 1.78%
65,506 $944 Million
Q3 2024

Sep 04, 2025

BUY
$16.03 - $20.31 $44,579 - $56,482
2,781 Added 4.35%
66,696 $1.3 Billion
Q2 2024

Sep 04, 2025

SELL
$16.36 - $21.78 $440,133 - $585,947
-26,903 Reduced 42.09%
37,012 $634 Million
Q1 2024

Sep 05, 2025

BUY
$12.08 - $18.56 $224,434 - $344,826
18,579 Added 43.31%
61,475 $1.03 Billion
Q4 2023

Sep 05, 2025

SELL
$16.25 - $20.23 $1.05 Million - $1.3 Million
-64,345 Reduced 60.0%
42,896 $777 Million
Q3 2023

Nov 07, 2025

BUY
$11.85 - $16.95 $532,823 - $762,139
44,964 Added 72.2%
107,241 $1.82 Billion
Q3 2023

Nov 03, 2025

SELL
$11.85 - $16.95 $19,410 - $27,764
-1,638 Reduced 2.56%
62,277 $981 Million
Q3 2023

Sep 05, 2025

SELL
$11.85 - $16.95 $2,607 - $3,729
-220 Reduced 0.2%
107,241 $1.82 Billion
Q2 2023

Sep 05, 2025

BUY
$10.78 - $17.73 $83,620 - $137,531
7,757 Added 7.78%
107,461 $1.29 Billion
Q1 2023

Sep 05, 2025

BUY
$13.02 - $19.87 $465,972 - $711,127
35,789 Added 55.99%
99,704 $1.3 Billion

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.61B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Abn Amro Investment Solutions Portfolio

Follow Abn Amro Investment Solutions and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abn Amro Investment Solutions, based on Form 13F filings with the SEC.

News

Stay updated on Abn Amro Investment Solutions with notifications on news.